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Treating Sleep Problems of People in 
Recovery From Substance Use Disorders
Sleep problems are a common complaint among people 
with substance use disorders (SUDs). They can occur 
during withdrawal, but they can also last months and 
years into recovery1 and can be associated with relapse to 
substance use.2 This In Brief alerts healthcare providers 
to the relationship between sleep disturbances and SUDs 
and provides guidance on how to assess for and treat sleep 
problems in patients in recovery.
Sleep Disturbances and Substance 
Use
Many Americans suffer from unhealthy sleep-related 
behaviors. The prevalence of insomnia symptoms 
(difficulty initiating or maintaining sleep) in the general 
population is estimated at 33 percent, with an estimated 
6 percent having a diagnosis of insomnia.3 According to 
a 12-state survey conducted by the Centers for Disease 
Control and Prevention:4
■ 35.3 percent of survey respondents obtain less than 
7 hours of sleep on average during a 24-hour period.
■ 48.0 percent snore.
■ 37.9 percent unintentionally fall asleep during the day.
Substance/medication-induced sleep disorder is 
recognized in the Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition.5 Substance use can 
exacerbate sleep difficulties, which in turn present a risk 
factor for substance use or relapse to use.6 The types of 
sleep problems vary by substance used and can include 
insomnia, sleep latency (the time it takes to fall asleep), 
disturbances in sleep cycles and sleep continuity, or 
hypersomnia (excessive daytime sleepiness).5 Specific 
findings on the relationship between sleep disturbances 
and substance use are presented below.
Alcohol Abuse
Insomnia and other sleep disturbances are common 
symptoms of alcohol dependence.1,7 Many people with 
alcohol use disorder (AUD) have insomnia before entering 
treatment.7 Reported rates of sleep problems among people 
with AUD in treatment range from 25 to 72 percent.8
Some people in recovery from AUD may continue to have 
sleep problems, including insomnia or sleep-disordered 
breathing (such as sleep apnea), for weeks, months, or 
sometimes years after initiating abstinence.9,10,11
Illicit Drug Use
Sleep disturbances are common among people abstaining 
from chronic substance use. People stopping marijuana 
use can experience sleep problems in the first days of 
withdrawal,12 and these problems can last for weeks.13,14 
People in detoxification from opioids often report 
symptoms of insomnia.15,16 A study that objectively 
measured sleep in people who chronically use cocaine 
found that sleep quality deteriorated during a period of 
abstinence, even though the subjects perceived their sleep 
to be improving.17 Another study of people in withdrawal 
from cocaine found that three-quarters experienced poor 
sleep quality.18 In a study of college students, those who 
reported a history of nonmedical psychostimulant use or 
current use reported worse subjective and overall sleep 
quality and more sleep disturbance compared with those 
who had not used such substances.19
The Effects of Sleep Loss During 
Recovery
Sleep loss can have significant negative effects on the 
physical, mental, and emotional well-being of people in 
recovery. It can also interfere with substance abuse 
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treatment. Persistent sleep complaints after withdrawal 
are associated with relapse to alcohol use.20,21 Poor sleep 
quality before a quit attempt from cannabis use is a risk 
factor for lapsing back into use within 2 days.22
Medication-Assisted Treatment 
and Sleep Disorders
Disrupted sleep, including central sleep apnea and related 
daytime sleepiness, is prevalent in people on methadone 
maintenance therapy for opioid dependence.23,24 Methadone 
dose and duration of opioid use prior to treatment correlate 
linearly with sleep problems.23 The prevalence of sleep 
problems is attributable to the methadone, which is a 
full µ-opioid agonist, and to concurrent factors that often 
affect patients in recovery from opioid addiction, such 
as mental disorders, benzodiazepine abuse, and chronic 
pain. Buprenorphine, a partial µ-opioid agonist, at routine 
therapeutic doses has also been found to induce significant 
alterations of breathing during sleep.25
Assessing Sleep Disorders
If a patient initiating withdrawal from a substance or 
recovering from an SUD complains of a sleep disturbance, 
the healthcare provider should assess for causes by doing 
the following:26
■ Determine the duration of recovery and medications 
used for SUD treatment.
■ Ask questions about difficulty falling asleep, waking 
during the night, amount of sleep per night, snoring, 
sleep apnea, excessive movements during sleep, 
uncontrollable movements that are relieved by getting 
up and walking, and excessive daytime sleepiness. 
If possible, ask significant others the same questions 
about the patient.
■ Rule out other causes of the sleep problem, such as 
stress, a life crisis, or side effects of medications the 
patient is taking.
■ Ask the patient to write in a sleep diary or log 
immediately on awakening. The patient should record 
total time in bed, time of sleep onset, number of times 
awakened, and total time spent awake.
■ Determine the frequency and duration of symptoms 
of insomnia. If difficulties occur two or three nights 
per week and last for 1 month or more, the patient 
warrants a diagnosis of insomnia.
Note that some patients tend to overestimate the quality 
and duration of their sleep on self-report questionnaires 
and in sleep logs.27,28 If warranted, a referral for an 
objective sleep study in a sleep laboratory can be made.
What Healthcare Providers Can Do
■ Screen for insomnia among people in recovery from SUDs.
■ Include questions about sleep during the routine patient history.
■ Rule out other causes of sleep problems (e.g., stress, medications).
■ Educate patients about sleep hygiene, and make referrals to a specialist if necessary.
■ Conduct a careful evaluation, and consider risk factors, before prescribing sedative–hypnotic medications to treat insomnia.
■ Monitor patients for signs of abuse or diversion of scheduled medications prescribed to treat insomnia and other sleep 
disorders.
Treatments
The association between insomnia and relapse calls for 
treatment that addresses insomnia during recovery. The 
first step in treating insomnia should focus on the status 
of the patient’s recovery. Patients should be receiving 
treatment from an appropriate substance abuse treatment 
program. It is important to address other psychological, 
social, and medical problems that may contribute to 
insomnia, such as co-occurring mental and medical 
disorders, use of medications that disturb sleep, and 
nicotine use.29,30
Nonpharmacological Treatments
Nonpharmacological treatments are preferred because 
many pharmacological treatments for insomnia have the 
potential for abuse and can interfere with SUD recovery. 
Research on cognitive–behavioral therapy (CBT) to treat 
insomnia has shown positive results, generally26,31,32 and 
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also in patients who are alcohol dependent.40 Exhibit 1 lists 
several nonpharmacological interventions that have shown 
some degree of effectiveness. Combining approaches may 
be more effective than using one approach.38
Healthcare providers can educate patients about simple 
nonpharmacological techniques that can improve sleep41
(see Exhibit 2). Sleep education includes teaching about 
sleep, the effects of recovery from substance use on sleep, 
and health practices and environmental factors that affect 
sleep.38 Sleep can be improved by limiting bedroom 
activities to sleeping (e.g., refraining from activities such 
as reading the newspaper, paying bills, or working on 
electronic devices) and going to bed only when sleepy 
and at about the same time each day. These activities help 
reassociate the bed and bedroom with going to sleep.37
Establishing a relaxing presleep routine, which can include 
progressive muscle relaxation,35 imagery,42 or a warm 
bath,41 also promotes sleep. Some patients may benefit 
from referral to a sleep medicine specialist.Exhibit 1. Nonpharmacological Treatments
■ Mindfulness meditation. The patient moves into 
a state of restful, present-moment alertness, which 
reduces stress and improves self-control.33,34
■ Progressive muscle relaxation. The patient 
concentrates on tensing and relaxing groups of 
muscles.8,35
■ Biofeedback. The patient becomes aware of 
physiologic stress responses and how to control them.26
■ CBT for insomnia. The patient’s dysfunctional beliefs 
and behaviors are modified to improve his or her 
emotional state.26,36
■ Stimulus control. The patient reassociates the bedroom 
with the rapid onset of sleep.37
■ Exercise. Regular physical activity relieves stress and 
tires the patient.26
■ Sleep restriction therapy. The patient limits sleep 
to a few hours and progressively increases it until the 
desired amount of sleep time is achieved.26
■ Bright-light therapy. Exposure to a natural bright light 
while awake helps promote normal sleep patterns.38
■ Dental devices and continuous positive airway 
pressure machines. These devices help the patient 
with obstructive sleep apnea breathe more easily 
during sleep.39
Pharmacological Treatments
Over-the-counter medications and dietary 
supplements
Some people who have trouble sleeping have tried over-
the-counter sleep medications or dietary supplements to 
help them sleep. Patients may ask about these, and care 
should be taken to explain their safety and efficacy. Many 
over-the-counter sleep medications contain antihistamines 
that cause sedation.38 They are not recommended as a 
long-term treatment for insomnia because they negatively 
affect the natural sleep cycle and have side effects such 
as morning grogginess, daytime sleepiness, and impaired 
alertness and judgment.43,44 Furthermore, evidence 
supporting their long-term effectiveness is insufficient.43
Popular dietary supplements taken with the intent to 
promote sleep include valerian and melatonin. Valerian, 
an herb, is thought to have sedative effects.45,46 However, 
studies of valerian offer mixed results,47,48 and evidence 
supporting the supplement’s efficacy is insufficient to 
warrant its use.49,50 In addition, valerian could damage the 
liver.47 Melatonin is a brain hormone that helps regulate 
sleep patterns.51 Limited evidence shows that it can treat 
chronic insomnia in some people and, to date, there is no 
evidence that it is harmful.52
Prescription medications without known 
abuse potential
Medications without known abuse potential should be the 
first treatment option when pharmacotherapy is necessary 
to treat insomnia during recovery. Ramelteon and doxepin 
are the only unscheduled prescription medications 
approved by the U.S. Food and Drug Administration 
(FDA) for the treatment of insomnia. Ramelteon decreases 
the amount of time it takes to fall asleep.53,54 Doxepin, 
originally FDA approved as an antidepressant, has been 
approved for treating insomnia typified by problems 
staying asleep. These medications may be suitable for 
treating insomnia in patients in recovery, because they do 
not appear to have potential for abuse.55,56,57
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Exhibit 2. Promoting Sleep Hygiene: Tips for a Good Night’s Sleep58,59
■ Go to bed and get up at the same times each day.
■ Use natural light (that comes through a window) to remind yourself of when it’s time to be asleep and awake. This can help 
you set a healthy sleep–wake cycle.
■ Exercise regularly. 
■ If you take naps, keep them short and before 5 p.m.
■ Don’t eat or drink too much when it is close to bedtime.
■ Avoid caffeine (in coffee, tea, chocolate, cola, and some pain relievers) and nicotine for several hours before bedtime.
■ Wind down before going to bed (e.g., take a warm bath, do light reading, practice relaxation exercises).
■ Keep the bedroom a relaxing place—avoid working or paying bills in bed. 
■ Sleep in a dark, quiet room that isn’t too hot or too cold.
■ Don’t lie in bed awake. If you can’t fall asleep within 20 minutes, get up and do something relaxing.
Off-label medications
Other medications are often prescribed off label (for 
purposes other than the medication’s FDA-approved use) 
to treat insomnia. According to a survey of addiction 
medicine physicians, the sedating antidepressant 
trazodone is the medication most often prescribed for 
the management of sleep disorders in patients in early 
recovery from AUD.60 One study found that its use among 
people in recovery from AUD improved sleep efficiency.61
Studies of its effects on abstinence and relapse in persons 
with AUD are conflicting. A 2008 study comparing 
trazodone with placebo for people after detoxification from 
alcohol showed that the trazodone group had improved 
sleep quality but had less improvement in the proportion of 
days abstinent while taking the medication. Furthermore, 
when the medication was discontinued, the trazodone 
group experienced less improvement in abstinence days 
and an increase in the number of drinks per drinking 
day.62 In contrast, a study published in 2011 of patients 
discharged from residential treatment did not find an 
association between trazodone use and relapse or return 
to heavy drinking.63 A study of patients on methadone 
maintenance treatment found that trazodone use provided 
no improvement in sleep.64
Other sedating antidepressants that have been used to treat 
insomnia include amitriptyline, mirtazapine, nefazodone, 
and nortriptyline.65 In a study of the use of mirtazapine 
on subjects with cocaine dependence and co-occurring 
depression, the medication decreased sleep latency; 
however, it had no measurable effect on treatment for 
cocaine dependence and depressive symptoms.66
Gabapentin, an anticonvulsant with sedative properties, 
also has evidence of efficacy for treating insomnia.50,67 It 
has been found to be more effective in promoting sleep 
than lorazepam (an anxiolytic commonly prescribed to 
treat insomnia) among people withdrawing from alcohol.67
It has also been found to be more effective than trazodone 
in promoting sleep among those in early recovery.68
Acamprosate, a medication used to maintain alcohol 
abstinence, may also improve sleep during withdrawal 
from alcohol.21,69
Prescription medications with known 
abuse potential
Sedative–hypnotic medications, such as benzodiazepines 
and nonbenzodiazepines, are commonly prescribed to 
treat sleep problems. However, these medications should 
be avoided by people with histories of SUDs, who are at 
increased risk for abusing them.44,70 Benzodiazepines, such 
as alprazolam, diazepam, and triazolam, are especially 
risky for use with people with SUDs because they are 
potentially addicting. They can also cause residual daytime 
sedation, cognitive impairment, motor incoordination, and 
rebound insomnia.50 Long-term treatment of insomnia with 
benzodiazepines may lead to withdrawal symptoms (e.g., 
anxiety, irritability, seizures) when patients stop taking 
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the medications. A careful clinical evaluation is needed to 
ensure appropriate prescribing. Measures to prevent abuse 
include the following:71
■ Observe closely and perform ongoing evaluations.
■ Prescribe a few tablets at a time.
■ Schedule frequent office visits.
■ Conduct occasional urine screenings.
■ Use one source to dispense the medication.
■ Occasionally taper the medication.
■ Be attentive to risk factors such as antisocial 
personality disorder and dependence on multiple 
substances.
Alternatives to benzodiazepines include sedative–hypnotic 
medications such as zaleplon, eszopiclone, and zolpidem. 
These medications all have the same mechanism of 
action as benzodiazepines but lack some of the negative 
side effects. However, some research indicates that 
at high doses they may have the same side effects as 
benzodiazepines.72 The three medications are Schedule IV 
controlled substances, indicating abuse potential. For
these reasons, these medications should be used only for 
short-term treatment of insomnia in people with a history 
of SUDs.
Web Resources
American Academy of Sleep Medicine 
http://www.aasmnet.org
National Center on Sleep Disorders Research 
http://www.nhlbi.nih.gov/about/org/ncsdr
National Sleep Foundation 
http://www.sleepfoundation.org
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